Cargando…
HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma
SIMPLE SUMMARY: HO-1089 and HO-1197 have potential to be developed as herbal medicine or as part of combination therapy in HCC. Additionally, development of PLK1 inhibition as a therapeutic strategy for HCC will require more study into the selection of patients based upon molecular vulnerabilities a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913440/ https://www.ncbi.nlm.nih.gov/pubmed/36765811 http://dx.doi.org/10.3390/cancers15030851 |
_version_ | 1784885427992264704 |
---|---|
author | Song, Yeonhwa Lee, Su-Yeon Kim, Sanghwa Choi, Inhee Kim, Namjeong Park, Jongmin Seo, Haeng Ran |
author_facet | Song, Yeonhwa Lee, Su-Yeon Kim, Sanghwa Choi, Inhee Kim, Namjeong Park, Jongmin Seo, Haeng Ran |
author_sort | Song, Yeonhwa |
collection | PubMed |
description | SIMPLE SUMMARY: HO-1089 and HO-1197 have potential to be developed as herbal medicine or as part of combination therapy in HCC. Additionally, development of PLK1 inhibition as a therapeutic strategy for HCC will require more study into the selection of patients based upon molecular vulnerabilities and the development of mechanism-based, rationally-selected combination of herbs. ABSTRACT: The treatment for hepatocellular carcinoma (HCC), a severe cancer with a very high mortality rate, begins with the surgical resection of the primary tumor. For metastasis or for tumors that cannot be resected, sorafenib, a multi-tyrosine protein kinase inhibitor, is usually the drug of choice. However, typically, neither resection nor sorafenib provides a cure. The drug discovery strategy for HCC therapy is shifting from monotherapies to combination regimens that combine an immuno-oncology agent with an angiogenesis inhibitor. Herbal formulas can be included in the combinations used for this personalized medicine approach. In this study, we evaluated the HCC anticancer efficacy of the new herbal formula, HO-1089. Treatment with HO-1089 inhibited HCC tumor growth by inducing DNA damage-mediated apoptosis and by arresting HCC cell replication during the G2/M phase. HO-1089 also attenuated the migratory capacity of HCC cells via the inhibition of the expression of EMT-related proteins. Biological pathways involved in metabolism and the mitotic cell cycle were suppressed in HO-1089-treated HCC cells. HO-1089 attenuated expression of the G2/M phase regulatory protein, PLK1 (polo-like kinase 1), in HCC cells. HCC xenograft mouse models revealed that the daily oral administration of HO-1089 retarded tumor growth without systemic toxicity in vivo. The use of HO-1197, a novel herbal formula derived from HO-1089, resulted in statistically significant improved anticancer efficacy relative to HO-1089 in HCC. These results suggest that HO-1089 is a safe and potent integrated natural medicine for HCC therapy. |
format | Online Article Text |
id | pubmed-9913440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99134402023-02-11 HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma Song, Yeonhwa Lee, Su-Yeon Kim, Sanghwa Choi, Inhee Kim, Namjeong Park, Jongmin Seo, Haeng Ran Cancers (Basel) Article SIMPLE SUMMARY: HO-1089 and HO-1197 have potential to be developed as herbal medicine or as part of combination therapy in HCC. Additionally, development of PLK1 inhibition as a therapeutic strategy for HCC will require more study into the selection of patients based upon molecular vulnerabilities and the development of mechanism-based, rationally-selected combination of herbs. ABSTRACT: The treatment for hepatocellular carcinoma (HCC), a severe cancer with a very high mortality rate, begins with the surgical resection of the primary tumor. For metastasis or for tumors that cannot be resected, sorafenib, a multi-tyrosine protein kinase inhibitor, is usually the drug of choice. However, typically, neither resection nor sorafenib provides a cure. The drug discovery strategy for HCC therapy is shifting from monotherapies to combination regimens that combine an immuno-oncology agent with an angiogenesis inhibitor. Herbal formulas can be included in the combinations used for this personalized medicine approach. In this study, we evaluated the HCC anticancer efficacy of the new herbal formula, HO-1089. Treatment with HO-1089 inhibited HCC tumor growth by inducing DNA damage-mediated apoptosis and by arresting HCC cell replication during the G2/M phase. HO-1089 also attenuated the migratory capacity of HCC cells via the inhibition of the expression of EMT-related proteins. Biological pathways involved in metabolism and the mitotic cell cycle were suppressed in HO-1089-treated HCC cells. HO-1089 attenuated expression of the G2/M phase regulatory protein, PLK1 (polo-like kinase 1), in HCC cells. HCC xenograft mouse models revealed that the daily oral administration of HO-1089 retarded tumor growth without systemic toxicity in vivo. The use of HO-1197, a novel herbal formula derived from HO-1089, resulted in statistically significant improved anticancer efficacy relative to HO-1089 in HCC. These results suggest that HO-1089 is a safe and potent integrated natural medicine for HCC therapy. MDPI 2023-01-30 /pmc/articles/PMC9913440/ /pubmed/36765811 http://dx.doi.org/10.3390/cancers15030851 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Song, Yeonhwa Lee, Su-Yeon Kim, Sanghwa Choi, Inhee Kim, Namjeong Park, Jongmin Seo, Haeng Ran HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma |
title | HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma |
title_full | HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma |
title_fullStr | HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma |
title_full_unstemmed | HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma |
title_short | HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma |
title_sort | ho-1089 and ho-1197, novel herbal formulas, have antitumor effects via suppression of plk1 (polo-like kinase 1) expression in hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913440/ https://www.ncbi.nlm.nih.gov/pubmed/36765811 http://dx.doi.org/10.3390/cancers15030851 |
work_keys_str_mv | AT songyeonhwa ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma AT leesuyeon ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma AT kimsanghwa ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma AT choiinhee ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma AT kimnamjeong ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma AT parkjongmin ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma AT seohaengran ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma |